- Cancer diagnostics is a strongly evolving field. Biovica’s novel cancer test can detect breast cancer progress cheaper and much faster than current methods. Biovica is the global leader in the field
- Its unprecedented 30 clinical trials in the prominent US and European hospitals minimize the risk of FDA failure. Biovica expects FDA approval and US launch by the Q3 end.
- Share prices of pharma companies tend to move strongly before a major catalyst. Biovica should be a perfect example of this.
- Biovica is up almost 40% in last two weeks. This trend is most likely going to continue for at least one more month prior to FDA. The recent price move may indicate, that the FDA may come sooner than currently expected August.
- My price target in six weeks (prior to FDA) is 100-140 SEK. The current share price is 60 SEK. Very good upside for one month and half.
Full investment thesis